Switching from other agents to extended-release carbamazepine in acute mania.

Rif S. El-Mallakh, Terence A. Ketter, Richard H. Weisler, Robert Hirschfeld, Andrew J. Cutler, Thomas Gazda, Paul Keck, Alan C. Swann, Amir H. Kalali

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

There is a dearth of available knowledge relating to the efficacy of switching from one psychotropic agent to another in treating patients with acute mania. This is a post hoc analysis of data from two randomized, placebo-controlled trials of carbamazepine extended-release capsules (CBZ-ERC) in the treatment of mania, to evaluate the efficacy of CBZ-ERC in patients previously nonresponsive to lithium (n 5 40), olanzapine (n 5 38), or valproate (VPA, n 5 77). In patients previously on lithium, Young Mania Rating Scale (YMRS) scores improved significantly from baseline to end point (27.4 6 SD 3.5 vs. 15.8 6 11.1; P 5 .0002). In patients previously on VPA or olanzapine, YMRS scores significantly improved in both CBZ-ERC- and placebo-treated groups (VPA: CBZ-ERC, P , .0001; placebo, P 5 .0002; olanzapine: CBZ-ERC, P , .0001; placebo, P 5 .0054). Improvement in YMRS was significantly greater in CBZ-ERC-treated patients versus placebo in subjects previously nonresponsive to lithium (CBZ-ERC 11.6 6 10.3 vs. placebo 4.0 6 11.2, P 5 .03), or VPA (CBZ-ERC 10.8 6 11.9 vs. placebo 5.7 6 9.2; P 5 .04), and trending to be greater for those previously nonresponsive to olanzapine (olanzapine 13.2 6 9.3 vs. placebo 7.3 6 9.7, P 5 .06). CBZ-ERC is an effective therapy for bipolar patients previously nonresponsive to lithium or valproate. Medication switch is frequently associated with symptom improvement.

Original languageEnglish (US)
Pages (from-to)52-58
Number of pages7
JournalPsychopharmacology Bulletin
Volume41
Issue number1
StatePublished - 2008

Fingerprint

olanzapine
Carbamazepine
Bipolar Disorder
Capsules
Placebos
Lithium
Valproic Acid
Randomized Controlled Trials
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

El-Mallakh, R. S., Ketter, T. A., Weisler, R. H., Hirschfeld, R., Cutler, A. J., Gazda, T., ... Kalali, A. H. (2008). Switching from other agents to extended-release carbamazepine in acute mania. Psychopharmacology Bulletin, 41(1), 52-58.

Switching from other agents to extended-release carbamazepine in acute mania. / El-Mallakh, Rif S.; Ketter, Terence A.; Weisler, Richard H.; Hirschfeld, Robert; Cutler, Andrew J.; Gazda, Thomas; Keck, Paul; Swann, Alan C.; Kalali, Amir H.

In: Psychopharmacology Bulletin, Vol. 41, No. 1, 2008, p. 52-58.

Research output: Contribution to journalArticle

El-Mallakh, RS, Ketter, TA, Weisler, RH, Hirschfeld, R, Cutler, AJ, Gazda, T, Keck, P, Swann, AC & Kalali, AH 2008, 'Switching from other agents to extended-release carbamazepine in acute mania.', Psychopharmacology Bulletin, vol. 41, no. 1, pp. 52-58.
El-Mallakh RS, Ketter TA, Weisler RH, Hirschfeld R, Cutler AJ, Gazda T et al. Switching from other agents to extended-release carbamazepine in acute mania. Psychopharmacology Bulletin. 2008;41(1):52-58.
El-Mallakh, Rif S. ; Ketter, Terence A. ; Weisler, Richard H. ; Hirschfeld, Robert ; Cutler, Andrew J. ; Gazda, Thomas ; Keck, Paul ; Swann, Alan C. ; Kalali, Amir H. / Switching from other agents to extended-release carbamazepine in acute mania. In: Psychopharmacology Bulletin. 2008 ; Vol. 41, No. 1. pp. 52-58.
@article{6c826b2004784d17b4c8db4c64924db9,
title = "Switching from other agents to extended-release carbamazepine in acute mania.",
abstract = "There is a dearth of available knowledge relating to the efficacy of switching from one psychotropic agent to another in treating patients with acute mania. This is a post hoc analysis of data from two randomized, placebo-controlled trials of carbamazepine extended-release capsules (CBZ-ERC) in the treatment of mania, to evaluate the efficacy of CBZ-ERC in patients previously nonresponsive to lithium (n 5 40), olanzapine (n 5 38), or valproate (VPA, n 5 77). In patients previously on lithium, Young Mania Rating Scale (YMRS) scores improved significantly from baseline to end point (27.4 6 SD 3.5 vs. 15.8 6 11.1; P 5 .0002). In patients previously on VPA or olanzapine, YMRS scores significantly improved in both CBZ-ERC- and placebo-treated groups (VPA: CBZ-ERC, P , .0001; placebo, P 5 .0002; olanzapine: CBZ-ERC, P , .0001; placebo, P 5 .0054). Improvement in YMRS was significantly greater in CBZ-ERC-treated patients versus placebo in subjects previously nonresponsive to lithium (CBZ-ERC 11.6 6 10.3 vs. placebo 4.0 6 11.2, P 5 .03), or VPA (CBZ-ERC 10.8 6 11.9 vs. placebo 5.7 6 9.2; P 5 .04), and trending to be greater for those previously nonresponsive to olanzapine (olanzapine 13.2 6 9.3 vs. placebo 7.3 6 9.7, P 5 .06). CBZ-ERC is an effective therapy for bipolar patients previously nonresponsive to lithium or valproate. Medication switch is frequently associated with symptom improvement.",
author = "El-Mallakh, {Rif S.} and Ketter, {Terence A.} and Weisler, {Richard H.} and Robert Hirschfeld and Cutler, {Andrew J.} and Thomas Gazda and Paul Keck and Swann, {Alan C.} and Kalali, {Amir H.}",
year = "2008",
language = "English (US)",
volume = "41",
pages = "52--58",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "1",

}

TY - JOUR

T1 - Switching from other agents to extended-release carbamazepine in acute mania.

AU - El-Mallakh, Rif S.

AU - Ketter, Terence A.

AU - Weisler, Richard H.

AU - Hirschfeld, Robert

AU - Cutler, Andrew J.

AU - Gazda, Thomas

AU - Keck, Paul

AU - Swann, Alan C.

AU - Kalali, Amir H.

PY - 2008

Y1 - 2008

N2 - There is a dearth of available knowledge relating to the efficacy of switching from one psychotropic agent to another in treating patients with acute mania. This is a post hoc analysis of data from two randomized, placebo-controlled trials of carbamazepine extended-release capsules (CBZ-ERC) in the treatment of mania, to evaluate the efficacy of CBZ-ERC in patients previously nonresponsive to lithium (n 5 40), olanzapine (n 5 38), or valproate (VPA, n 5 77). In patients previously on lithium, Young Mania Rating Scale (YMRS) scores improved significantly from baseline to end point (27.4 6 SD 3.5 vs. 15.8 6 11.1; P 5 .0002). In patients previously on VPA or olanzapine, YMRS scores significantly improved in both CBZ-ERC- and placebo-treated groups (VPA: CBZ-ERC, P , .0001; placebo, P 5 .0002; olanzapine: CBZ-ERC, P , .0001; placebo, P 5 .0054). Improvement in YMRS was significantly greater in CBZ-ERC-treated patients versus placebo in subjects previously nonresponsive to lithium (CBZ-ERC 11.6 6 10.3 vs. placebo 4.0 6 11.2, P 5 .03), or VPA (CBZ-ERC 10.8 6 11.9 vs. placebo 5.7 6 9.2; P 5 .04), and trending to be greater for those previously nonresponsive to olanzapine (olanzapine 13.2 6 9.3 vs. placebo 7.3 6 9.7, P 5 .06). CBZ-ERC is an effective therapy for bipolar patients previously nonresponsive to lithium or valproate. Medication switch is frequently associated with symptom improvement.

AB - There is a dearth of available knowledge relating to the efficacy of switching from one psychotropic agent to another in treating patients with acute mania. This is a post hoc analysis of data from two randomized, placebo-controlled trials of carbamazepine extended-release capsules (CBZ-ERC) in the treatment of mania, to evaluate the efficacy of CBZ-ERC in patients previously nonresponsive to lithium (n 5 40), olanzapine (n 5 38), or valproate (VPA, n 5 77). In patients previously on lithium, Young Mania Rating Scale (YMRS) scores improved significantly from baseline to end point (27.4 6 SD 3.5 vs. 15.8 6 11.1; P 5 .0002). In patients previously on VPA or olanzapine, YMRS scores significantly improved in both CBZ-ERC- and placebo-treated groups (VPA: CBZ-ERC, P , .0001; placebo, P 5 .0002; olanzapine: CBZ-ERC, P , .0001; placebo, P 5 .0054). Improvement in YMRS was significantly greater in CBZ-ERC-treated patients versus placebo in subjects previously nonresponsive to lithium (CBZ-ERC 11.6 6 10.3 vs. placebo 4.0 6 11.2, P 5 .03), or VPA (CBZ-ERC 10.8 6 11.9 vs. placebo 5.7 6 9.2; P 5 .04), and trending to be greater for those previously nonresponsive to olanzapine (olanzapine 13.2 6 9.3 vs. placebo 7.3 6 9.7, P 5 .06). CBZ-ERC is an effective therapy for bipolar patients previously nonresponsive to lithium or valproate. Medication switch is frequently associated with symptom improvement.

UR - http://www.scopus.com/inward/record.url?scp=84858068991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858068991&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 52

EP - 58

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 1

ER -